Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / KLK8



This biomarker is also known as:
  • TADG14,
  • NRPN,
  • Serine protease 19,
  • hK8,
  • PRSS19,
  • kallikrein-related peptidase 8,
  • Neuropsin,
  • HNP,
  • kallikrein 8 (neuropsin/ovasin),
  • Tumor-associated differentially expressed gene 14 protein,
  • Ovasin,
  • neuropsin,
  • NP,
  • Serine protease TADG-14,
  • ovasin,

View in BioMuta


KLK8, a member of the kallikrein subgroup of serine proteases, is capable of degrading a number of proteins such as casein, fibrinogen, kininogen, fibronectin and collagen type IV. Kallikreins have been implicated in carcinogenesis, and some have potential as novel cancer and other disease biomarkers. KLK8 is one of fifteen kallikrein subfamily members located in a cluster on chromosome 19. The four isoforms of KLK8 are a result of alternate splicing of the gene. The isoforms exhibit distinct patterns of expression that suggest roles in brain plasticity and ovarian cancer.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


KLK8 alone was not shown to be a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.